[go: up one dir, main page]

MA63525B1 - Compositions d'oligonucléotides et leurs procédés de préparation - Google Patents

Compositions d'oligonucléotides et leurs procédés de préparation

Info

Publication number
MA63525B1
MA63525B1 MA63525A MA63525A MA63525B1 MA 63525 B1 MA63525 B1 MA 63525B1 MA 63525 A MA63525 A MA 63525A MA 63525 A MA63525 A MA 63525A MA 63525 B1 MA63525 B1 MA 63525B1
Authority
MA
Morocco
Prior art keywords
free
amino group
bond
protected
dinucleotide
Prior art date
Application number
MA63525A
Other languages
English (en)
Other versions
MA63525A1 (fr
Inventor
Premchandran H. Ramiya
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of MA63525A1 publication Critical patent/MA63525A1/fr
Publication of MA63525B1 publication Critical patent/MA63525B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne un procédé en phase solide pour préparer des oligonucléotides par l'intermédiaire de cycles de couplages séquentiels comprenant au moins un couplage d'un sous-motif dimère dinucléotidique à un groupe 3'-terminal libre d'une chaîne en cours d'allongement. Les oligonucléotides comprennent au moins deux sous-motifs nucléosidiques reliés par une liaison N3'→ P5'phosphoramidate. Le procédé peut comprendre les étapes de (a) déprotection du groupe 3'-amino protégé d'un nucléoside terminal immobilisé sur un support en phase solide, ladite déprotection formant un groupe 3'-amino libre ; (b) mise en contact du groupe 3'-amino libre avec un dimère 3'-amino protégé-dinucléotide-5'-phosphoramidite en présence d'un catalyseur nucléophile pour former une liaison internucléosidique N3'→ P5' ; et (c) oxydation (p. ex., sulfuration) de la liaison. Les compositions produites par les présents procédés peuvent contenir une quantité réduite d'un ou de plusieurs produits oligonucléotidiques (N-x). Des compositions pharmaceutiques contenant les présentes compositions d'oligonucléotides sont en outre décrites.
MA63525A 2014-05-01 2015-04-29 Compositions d'oligonucléotides et leurs procédés de préparation MA63525B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US201562151909P 2015-04-23 2015-04-23

Publications (2)

Publication Number Publication Date
MA63525A1 MA63525A1 (fr) 2024-09-30
MA63525B1 true MA63525B1 (fr) 2025-02-28

Family

ID=54359301

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63525A MA63525B1 (fr) 2014-05-01 2015-04-29 Compositions d'oligonucléotides et leurs procédés de préparation

Country Status (33)

Country Link
US (6) US9796747B2 (fr)
EP (2) EP4286519A3 (fr)
JP (6) JP7040892B2 (fr)
KR (4) KR20230088509A (fr)
CN (3) CN117357548A (fr)
AP (1) AP2016009489A0 (fr)
AU (3) AU2015253158B2 (fr)
BR (1) BR112016025196B1 (fr)
CL (4) CL2016002749A1 (fr)
DK (1) DK3137479T5 (fr)
EA (1) EA034882B9 (fr)
ES (1) ES2963740T3 (fr)
FI (1) FI3137479T3 (fr)
HR (1) HRP20231505T1 (fr)
HU (1) HUE064289T2 (fr)
IL (2) IL248044B (fr)
JO (2) JOP20200257A1 (fr)
LT (1) LT3137479T (fr)
MA (1) MA63525B1 (fr)
MX (2) MX382233B (fr)
MY (2) MY178617A (fr)
PE (1) PE20170147A1 (fr)
PH (1) PH12016502080A1 (fr)
PL (1) PL3137479T3 (fr)
PT (1) PT3137479T (fr)
RS (1) RS64860B1 (fr)
SG (2) SG11201608226YA (fr)
SI (1) SI3137479T1 (fr)
SM (1) SMT202300405T1 (fr)
TW (2) TWI712413B (fr)
UA (1) UA126108C2 (fr)
WO (1) WO2015168310A1 (fr)
ZA (2) ZA201606624B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485717B2 (en) * 2004-07-02 2009-02-03 Geron Corporation Synthesis of protected 3′-amino nucleoside monomers
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
RS60645B1 (sr) 2015-04-23 2020-09-30 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
TWI775895B (zh) 2017-07-10 2022-09-01 美商傑龍公司 用於製備伊美司他之改進的方法
MX2022005007A (es) 2019-10-28 2022-08-08 Geron Corp Sólidos cristalinos de 3-palmitoil-amido-1, 2-propanodiol y 3-palmitoil-amido-2-hidroxi-1-dimetoxitrifenilmetileter-propano y métodos para elaborarlos y usarlos.
EP4523681A1 (fr) 2019-10-28 2025-03-19 Geron Corporation Sels solides amorphes de 3-(acide gras amido)-2-hydroxy-1-(hydroxy protege)-propane succinyle et leurs procedes de fabrication
EP4089099A4 (fr) * 2020-01-08 2024-07-24 Nitto Denko Corporation Procédé de synthèse d'acide nucléique utilisant un amidite de type segment
KR20250008345A (ko) 2023-07-07 2025-01-14 주식회사 엘지에너지솔루션 체결기구 및 체결기구를 포함하는 전지팩

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018015A1 (fr) * 1999-09-10 2001-03-15 Geron Corporation Thiophosphoramidates n3'→p5' oligonucleotidiques: synthese et utilisation
WO2002077184A2 (fr) * 2001-03-23 2002-10-03 Geron Corporation Conjugues d'oligonucleotide

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE69008521T2 (de) 1989-03-07 1994-10-20 Genentech Inc Kovalente konjugate von lipiden und oligonukleotiden.
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
WO1991014696A1 (fr) 1990-03-29 1991-10-03 Gilead Sciences, Inc. Conjugues a base de disulfure d'oligonucleotide et d'un agent de transport
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
CA2174425A1 (fr) 1993-10-18 1995-04-27 Graham Leslie Barrett Procede destine a amplifier la survie des neurones et agents utiles a cet effet
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
HUT76094A (en) 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
CN1231491C (zh) 1994-07-07 2005-12-14 杰龙公司 哺乳动物端粒酶
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
EP0790965A1 (fr) 1994-11-07 1997-08-27 HYBRIDON, Inc. Synthese d'oligonucleotides marques au ?35 s a l'aide de 3h-1,2-benzodithiol-3-one-1,1-dioxyde
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
ES2775525T3 (es) 2003-09-09 2020-07-27 Geron Corp Oligonucleótidos modificados para la inhibición de la telomerasa
US20120329858A1 (en) * 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
US7485717B2 (en) 2004-07-02 2009-02-03 Geron Corporation Synthesis of protected 3′-amino nucleoside monomers
US7427675B2 (en) * 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
CA2584984A1 (fr) * 2004-10-18 2006-04-27 Codon Devices, Inc. Procedes d'assemblage de polynucleotides synthetiques de haute fidelite
EP1876893B1 (fr) 2005-04-15 2012-04-11 Geron Corporation Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
WO2007127163A2 (fr) * 2006-04-24 2007-11-08 Geron Corporation Méthode et composition pour le traitement d'une tumeur du snc
PT2101789E (pt) 2006-10-30 2015-03-24 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018015A1 (fr) * 1999-09-10 2001-03-15 Geron Corporation Thiophosphoramidates n3'→p5' oligonucleotidiques: synthese et utilisation
US20070037770A1 (en) * 1999-09-10 2007-02-15 Sergei Gryaznov Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
WO2002077184A2 (fr) * 2001-03-23 2002-10-03 Geron Corporation Conjugues d'oligonucleotide

Also Published As

Publication number Publication date
JP7040892B2 (ja) 2022-03-23
MX382233B (es) 2025-03-13
BR112016025196A2 (pt) 2017-12-12
KR102316282B1 (ko) 2021-10-25
SG11201608226YA (en) 2016-10-28
JOP20200257A1 (ar) 2017-06-16
JP2020050670A (ja) 2020-04-02
SI3137479T1 (sl) 2023-11-30
PH12016502080A1 (en) 2017-01-09
DK3137479T5 (da) 2024-10-14
DK3137479T3 (da) 2023-11-20
US20220306676A1 (en) 2022-09-29
IL268570A (en) 2019-09-26
TW202017574A (zh) 2020-05-16
JP2023073510A (ja) 2023-05-25
CL2022000202A1 (es) 2023-02-10
KR102707216B1 (ko) 2024-09-19
KR20230088509A (ko) 2023-06-19
HUE064289T2 (hu) 2024-02-28
EA034882B9 (ru) 2020-07-13
EP3137479B1 (fr) 2023-08-30
US20250011359A1 (en) 2025-01-09
MX2016014178A (es) 2017-05-04
CN106459134B (zh) 2020-02-18
TWI709406B (zh) 2020-11-11
PT3137479T (pt) 2023-11-30
CN117357548A (zh) 2024-01-09
LT3137479T (lt) 2023-10-10
US20240150391A1 (en) 2024-05-09
MX2021004932A (es) 2021-08-16
JP7736489B2 (ja) 2025-09-09
AU2020201707A1 (en) 2020-03-26
TWI712413B (zh) 2020-12-11
SG10201911086XA (en) 2020-01-30
AU2022203273A1 (en) 2022-06-02
MY196927A (en) 2023-05-11
ES2963740T3 (es) 2024-04-01
CN111228288B (zh) 2023-10-20
JP2021182946A (ja) 2021-12-02
IL268570B (en) 2021-10-31
EA034882B1 (ru) 2020-04-01
US20180016293A1 (en) 2018-01-18
US9796747B2 (en) 2017-10-24
RS64860B1 (sr) 2023-12-29
CL2016002749A1 (es) 2017-04-28
AU2015253158A1 (en) 2016-10-20
JP7308309B2 (ja) 2023-07-13
CL2018001212A1 (es) 2018-08-03
WO2015168310A1 (fr) 2015-11-05
CN111228288A (zh) 2020-06-05
EP3137479A4 (fr) 2018-02-07
KR20210130822A (ko) 2021-11-01
PE20170147A1 (es) 2017-04-12
US10392418B2 (en) 2019-08-27
KR20160147768A (ko) 2016-12-23
HRP20231505T1 (hr) 2024-03-01
UA126108C2 (uk) 2022-08-17
ZA201606624B (en) 2020-12-23
NZ763996A (en) 2021-03-26
IL248044A0 (en) 2016-11-30
NZ724764A (en) 2021-02-26
TW201622732A (zh) 2016-07-01
BR112016025196B1 (pt) 2022-08-02
US11299511B2 (en) 2022-04-12
CL2018001213A1 (es) 2018-08-03
JP2022044679A (ja) 2022-03-17
JP2017514479A (ja) 2017-06-08
CN106459134A (zh) 2017-02-22
SMT202300405T1 (it) 2024-01-10
EP4286519A3 (fr) 2024-02-28
US11739114B2 (en) 2023-08-29
US20150337314A1 (en) 2015-11-26
JO3767B1 (ar) 2021-01-31
ZA202005857B (en) 2024-01-31
EP3137479A1 (fr) 2017-03-08
CA2943888A1 (fr) 2015-11-05
KR20240144488A (ko) 2024-10-02
EP4286519A2 (fr) 2023-12-06
AU2015253158B2 (en) 2019-12-12
PL3137479T3 (pl) 2024-02-26
AP2016009489A0 (en) 2016-10-31
EA201691786A1 (ru) 2017-04-28
JP2018131453A (ja) 2018-08-23
IL248044B (en) 2019-08-29
AU2020201707B2 (en) 2022-02-17
MY178617A (en) 2020-10-19
US20180016294A1 (en) 2018-01-18
FI3137479T3 (fi) 2023-11-28
MA63525A1 (fr) 2024-09-30

Similar Documents

Publication Publication Date Title
MA63525B1 (fr) Compositions d'oligonucléotides et leurs procédés de préparation
EA201690274A1 (ru) Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов
WO2008069906A3 (fr) Expression numérisée de l'analyse génétique
MX2014002854A (es) Metodos para etiquetar bibliotecas codificadas por adn.
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
EA201391400A1 (ru) Способ производства конъюгатов с улучшенной гомогенностью
WO2016161375A3 (fr) Procédés d'utilisation de protéines argonautes guidées par les oligonucléotides
WO2022084331A3 (fr) Nouveaux ligands pour le récepteur d'asialoglycoprotéine
MX2009005896A (es) Proceso y aparato para preparar metacrilatos de alquilo.
DE602006012971D1 (de) Vermittelter chemie
Kim et al. Degron-based bioPROTACs for controlling signaling in CAR T cells
RU2019119833A (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННАЯ миРНК
UA99793C2 (ru) Набор для определения вируса гепатита в
MA59673A1 (fr) Compositions d'oligonucléotides et leurs procédés de préparation
RU2009128762A (ru) Способ и набор для иммуноферментного определения функциональной активности компонента с3 комплемента человека
ZA202110555B (en) Improved process for preparing imetelstat
WO2011067450A8 (fr) Supports biofonctionnalisés de manière covalente
EA202090282A1 (ru) Композиции олигонуклеотидов и способы их получения
MX343244B (es) Método para la detección del hongo fitopatógeno colletotrichum capsici utilizando la reacción en cadena de la polimerasa (pcr).
UA54336U (ru) Способ выявления рнк вируса геморрагической септицемии форели при помощи обратно - транскриптазной полимеразной цепной реакции
Куклин C vs. P
UA51551U (uk) Спосіб виявлення рнк ентеровірусів свиней а методом зворотнотранскриптазної полімеразної ланцюгової реакції
MX345865B (es) Equipo y metodo para la deteccion del rubulavirus porcino.
MY194293A (en) A method for identifying hiv-1 variants